BACKGROUND: In the United States the overall participation in cancer clinical trials (CCT) is less than 3% [Avis et al. in J Clin Oncol 24:1860-1867 (2006); Lara et al. in J Clin Oncol 19:1728-1733 (2001)]. In Europe there is little data on participation in such trials. AIM: We aim to gather information on factors influencing CCT enrolment in Ireland. METHODS: From November 2005 to 28 February 2006 all consecutive patients considered for systemic therapy were assessed for eligibility re participation in available CCTs. RESULTS: A total of 290 patients were included. Overall 2.4% of patients were recruited to one of the available CCTs. The main reasons for failure of trial recruit were: no trial for cancer type (60%), no trial for stage (21%), ineligible by trial criteria (16.1%), patient declined (0.3%), and physician discretion (2.6%). Only one patient, who was otherwise eligible, declined entry into a clinical trial. CONCLUSIONS: Irish patients with cancer are very willing to participate in CCTs. Current levels of recruitment compare favourably with international levels.
BACKGROUND: In the United States the overall participation in cancer clinical trials (CCT) is less than 3% [Avis et al. in J Clin Oncol 24:1860-1867 (2006); Lara et al. in J Clin Oncol 19:1728-1733 (2001)]. In Europe there is little data on participation in such trials. AIM: We aim to gather information on factors influencing CCT enrolment in Ireland. METHODS: From November 2005 to 28 February 2006 all consecutive patients considered for systemic therapy were assessed for eligibility re participation in available CCTs. RESULTS: A total of 290 patients were included. Overall 2.4% of patients were recruited to one of the available CCTs. The main reasons for failure of trial recruit were: no trial for cancer type (60%), no trial for stage (21%), ineligible by trial criteria (16.1%), patient declined (0.3%), and physician discretion (2.6%). Only one patient, who was otherwise eligible, declined entry into a clinical trial. CONCLUSIONS: Irish patients with cancer are very willing to participate in CCTs. Current levels of recruitment compare favourably with international levels.
Authors: P N Lara; R Higdon; N Lim; K Kwan; M Tanaka; D H Lau; T Wun; J Welborn; F J Meyers; S Christensen; R O'Donnell; C Richman; S A Scudder; J Tuscano; D R Gandara; K S Lam Journal: J Clin Oncol Date: 2001-03-15 Impact factor: 44.544
Authors: Joy H Lewis; Meredith L Kilgore; Dana P Goldman; Edward L Trimble; Richard Kaplan; Michael J Montello; Michael G Housman; José J Escarce Journal: J Clin Oncol Date: 2003-04-01 Impact factor: 44.544
Authors: James R Wright; Timothy J Whelan; Susan Schiff; Sacha Dubois; Dauna Crooks; Patricia T Haines; Diane DeRosa; Robin S Roberts; Amiram Gafni; Kathleen Pritchard; Mark N Levine Journal: J Clin Oncol Date: 2004-11-01 Impact factor: 44.544
Authors: Michael S Simon; Wei Du; Lawrence Flaherty; Philip A Philip; Patricia Lorusso; Cheryl Miree; Daryn Smith; Diane R Brown Journal: J Clin Oncol Date: 2004-04-13 Impact factor: 44.544
Authors: Patricia A H Hamers; Marloes A G Elferink; Rebecca K Stellato; Cornelis J A Punt; Anne M May; Miriam Koopman; Geraldine R Vink Journal: Int J Cancer Date: 2020-07-20 Impact factor: 7.396
Authors: Orla M Fitzpatrick; Catherine Murphy; Erica Duignan; Keith Egan; Bryan T Hennessy; Liam Grogan; Adrian Murphy; Oscar S Breathnach; Jarushka Naidoo; Patrick G Morris Journal: Ir J Med Sci Date: 2022-01-17 Impact factor: 2.089